Skip to content
  • ENGLISHENGLISH
  • 繁體中文繁體中文
回首頁回首頁回首頁
  • About Alar
    • Company Profile
    • Leadership Team
    • History & Milestones
  • Products
    • Product Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Events
  • Investors
    • Stock Info
    • Financials
  • Contact Us
MENU Close

2022/12/05 ALA-1000 received notice of patent allowance from Companies and Intellectual Property Commission of Republic of South Africa , Application No. 2020/04582

2022/12/05 ALA-1000 received notice of patent allowance from Companies and Intellectual Property Commission of Republic of South Africa , Application No. 2020/04582

  • Post author:alarpharm
  • Post published:6 . 12 . 2022
  • Post category:Media releases

You Might Also Like

2021/11/30 ALA-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia, Application No. P00201902139..

17 . 12 . 2021

2023/08/21 ALA-3000 has received the Notice of Eligibility of Grant from Intellectual Property Office of Singapore (IPOS) after the examination.(Patent Application No. 11202104792S)

23 . 8 . 2023

2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

14 . 1 . 2022

2021/11/09 Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients

10 . 11 . 2021

2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April.

13 . 4 . 2021
  • News
  • Events
回首頁

ABOUT

  • Company Profile
  • Leadership Team
  • History & Milestones
  • Company Profile
  • Leadership Team
  • History & Milestones

PRODUCTS

  • Product Pipeline
  • Contract Manufacturing
  • Product Pipeline
  • Contract Manufacturing

MEDIA

  • News
  • Events
  • News
  • Events

INVESTORS

  • Stock Info
  • Financials
  • Stock Info
  • Financials

CONTACT US

  • Contact Us
  • Contact Us
  • Contact Us
  • Privacy Policy
Copyright © - 2022 Alar Pharmaceuticals Inc . All right reserved.
Close
  • About Alar
    • Company Profile
    • Leadership Team
    • History&Milestones
  • Products
    • Products Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Events
  • Investors
    • Stock Info
    • Financials
  • Contact Us
    • Contact Us
×

Cart